Press Alt+1 for screen-reader mode, Alt+0 to cancelAccessibility Screen-Reader Guide, Feedback, and Issue Reporting | New window
timothy sykes logo

Stock News

Celcuity Stock Soars on Positive Phase 3 Trial Data for Gedatolisib

Bryce TuoheyAvatar
Written by Bryce Tuohey Reviewed by Tim Sykes Fact-checked by Matt Monaco
Updated 11/14/2025, 4:38 pm ET | 5 min
Celcuity Stock Soars on Positive Phase 3 Trial Data for Gedatolisib Thumbnail

In this article Last trade Dec, 05 7:12 PM

  • CELC+0.22%
    CELC - NASDAQCelcuity Inc.
    $106.10+0.23 (+0.22%)
    Volume:  945363
    Float:  28.50M
    $105.00Day Low/High$107.78

Celcuity Inc. stocks have been trading up by 9.47 percent after promising results and FDA designations boost investor confidence.

Healthcare industry expert:

Analyst sentiment – positive

Market Position & Fundamentals: Celcuity’s current market outlook is characterized by significant challenges as evidenced by negative profitability ratios and high leverage ratios. With an EBIT margin of -39209000 and an enterprise value of $3.51 billion, the company is underperforming in terms of profitability. Its debt-to-equity ratio stands at a concerning 2.24, while return on equity and return on assets are -80.9 and -44.69, respectively, indicating significant inefficiencies in capital utilization. Despite a strong current ratio of 4.6 signaling strong liquidity, the negative cash flow of -24.9 highlights considerable financial distress and a need for operational improvement. Consequently, Celcuity must refocus on cost management and financial restructuring to shift its current trajectory.

Technical Analysis & Trading Strategy: Celcuity’s recent price action exhibits a bullish trend with strong upward momentum noted in its weekly price movements. A key breakout occurred as prices sharply rose from a low of 76.70 to a high of 94.145, indicating robust buying interest. The consistent upward momentum and the clear breakout above previous resistance levels suggest further potential upside. Given this momentum, a trading strategy would be to buy on dips with a stop-loss just below the support level of 85.26 and target a near-term resistance of 100, contingent on continued positive market sentiment and volume support.

Catalysts & Outlook: Recent catalysts include positive news from Celcuity’s announcement of successful Phase 3 trial results for Gedatolisib, leading to a 38% surge in share price. The company’s improved Q3 financials, beating analysts’ expectations, alongside favorable analyst revisions in target prices, underscores growing confidence in its clinical developments. Furthermore, increased institutional analysis reports and revised PTs by firms such as Stifel and Craig-Hallum bolster market perception. Looking ahead, Celcuity’s prospects are optimistic in comparison to its peers in the Biotechnology and Life Sciences sectors, particularly benefiting from positive trial outcomes and strategic market positioning. The defined support level of 85 and resistance at 115 guide potential price actions, with an overall bullish sentiment projected based on ongoing trial successes and strengthened financial forecasts.

Candlestick Chart

Weekly Update Nov 10 – Nov 14, 2025: On Friday, November 14, 2025 Celcuity Inc. stock [NASDAQ: CELC] is trending up by 9.47%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Celcuity’s recent earnings report sheds light on their improved but still challenging financial performance. The company reported an adjusted Q3 loss of $0.78 per share, narrower than the anticipated $0.96 loss, though still widened compared to last year’s $0.65 loss. Despite this, the company’s backing extends with funding assured through 2027, providing a critical financial buffer as they push forward with drug development and market strategies.

The company’s revenues and profitability margins have yet to reflect the positive fundamental changes brought by these advancements. Nevertheless, their improving clinical outcomes, alongside heightened investor confidence, suggest a potent foundation for future revenue growth. Financial strengths such as a current ratio of 4.6 and a quick ratio of 4.2 reflect solid liquidity, which will support ongoing R&D and commercialization efforts.

Celcuity’s balance sheet reveals robust cash positions, which will aid in funding its strategic expansions and operational needs. The enterprise value sits notably high at $3.51B, correlating with the market’s optimistic expectations. However, high debt levels and negative profitability ratios indicate areas where fiscal prudence must continue as they transition toward potential market-leading positions in oncology.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Bryce Tuohey

Mentor and Trainer at StocksToTrade.com, Lead Mentor at Small Cap Rockets and To The Moon Report
Bryce’s first pattern was buying into strength in breakouts. But he noticed when they didn’t work, he took bigger losses. When the OTC market got hot, Bryce learned to dip buy the inevitable panics. He adapted his breakout strategy and now buys consolidation and trend breaks. His goal is to have better risk/reward and get an entry before multi-day listed breakouts.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”

ts swipe photo
Learn The Formula That Has Created Over 50 Millionaires
TRADE LIKE TIM